JITC Digest December 2019


Inside this Issue:

Letter from the Editor

Dear JITC Readers,pedro-romero_1__1_.jpg

This is the final JITC digest of 2019, and we are ending the year on a historic note with December’s issue containing the most-ever papers published in a single month since the journal’s inception! It has been an exciting year for JITC, and we look forward to what the future holds as the immunotherapy field continues to expand and evolve.

The highlighted papers in this month’s JITC digest truly exemplify some of the most exciting areas of research in our field, spanning preclinical models to human trials and adding new insight into the contribution of the tumor microenvironment to disease progression and immunotherapy resistance as well as the development of novel immunotherapeutic agents.

Be sure to read the Editor Picks below about microenvironment-targeting therapeutics for the reprogramming of myeloid-derived suppressor cells and for the selective depletion of tumor-associated macrophages, gene-edited “off-the-shelf” CAR T cells for the treatment of glioblastoma, preclinical validation for a new checkpoint inhibitor target in ovarian cancer, newly described mechanisms of immunotherapy resistance in melanoma, a deeper understanding of the two types of secondary bone metastases in prostate cancer, and a phase 2 trial describing dendritic cell vaccines for prostate cancer that that induce clinically meaningful immune responses.

With best regards,
Pedro J. Romero, MD
Editor-in-Chief, Journal for ImmunoTherapy of Cancer

JITC Editor Picks

BTLA blockade enhances cancer therapy by inhibiting IL-6/IL-10-induced CD19high B lymphocytes

Yu-Li Chen, Han-Wei Lin, Chung-Liang Chien, Yen-Ling Lai, Wei-Zen Sun, Chi-An Chen & Wen-Fang Cheng
Journal for ImmunoTherapy of Cancer 2019, 7:313 (21 November 2019)


Epithelial ovarian carcinomas (EOCs) have a relatively poor prognosis when treated with standard of care surgery followed by platinum/paclitaxel-based chemotherapy, with an overall survival rate of roughly 35%. To investigate potential immunotherapeutic approaches for the treatment of EOCs, Chen and colleagues treated tumor-bearing mice with a monoclonal antibody directed against the immune checkpoint molecule B and T lymphocyte attenuator (BTLA). The survival of tumor-bearing mice receiving the anti-BTLA antibody was not significantly different than those treated with paclitaxel. However, a combination regimen significantly prolonged survival, with 100% of mice receiving both anti-BTLA antibody and paclitaxel remaining alive for more than 100 days after tumor challenge. Pro-inflammatory cytokines including IL-12 and TNF-alpha were elevated in ascites from mice treated with a combination of anti-BTLA antibody and paclitaxel compared to those that received either single agent. BTLA was predominantly expressed on CD19high B lymphocytes, and IL-6 as well as IL-10 further increased BTLA expression on CD19high B cells through AKT/STAT3 signaling. Detectable BTLA by qPCR in tumor samples from 254 human EOC patients was associated with higher incidence of advanced disease (p<0.001) and disease-related death (P<0.001). The results suggest BTLA inhibition may hold clinical potential when used in combination with chemotherapy for EOC patients.

CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma

Bryan D. Choi, Xiaoling Yu, Ana P. Castano, Henia Darr, Daniel B. Henderson, Amanda A. Bouffard, Rebecca C. Larson, Irene Scarfò, Stefanie R. Bailey, Genevieve M. Gerhard, Matthew J. Frigault, Mark B. Leick, Andrea Schmidts, Jason G. Sagert, William T. Curry, Bob S. Carter & Marcela V. Maus
Journal for ImmunoTherapy of Cancer 2019, 7:304 (14 November 2019)
Short Report


CAR T cell therapies have had limited success in the treatment of solid tumors, in part due to profound immune suppression within the tumor microenvironment including marked upregulation of PD-L1. To overcome tumor-induced T cell exhaustion and also develop an “off-the-shelf” universal allogenic CAR T cell product for the treatment of glioblastoma, Bryan Choi and colleagues deployed CRISPR-Cas9 for multiplex genome editing to disrupt the PD-1 gene (PDCD1) in addition to the endogenous T cell receptor (TRAC) and beta-2-microglobin loci (B2M) prior to introducing an anti-EGFRvIII CAR on an adenoviral vector (which allows for integration into the genome at a specific site) during the manufacturing process. The gene-edited CAR T cells lacking PD-1 showed significantly more cytotoxic activity against U87vIII glioblastoma cell lines in vitro than PD-1 proficient CAR T cells after up to 120 hours in coculture. In mouse models of EGFRvIII expressing glioblastoma, treatment with the gene-edited CAR T cells significantly prolonged survival with some animals displaying durable, long-term responses, but only when the cells were administered intracranially through intraventricular injection. This is the first report of triple deletion of TRACB2M and PDCD1 in CAR T cells tested in a solid tumor model, possibly overcoming some of the shortcomings of previous attempts to utilize CAR T cells for the treatment of glioblastoma.

Distinct tumor microenvironments of lytic and blastic bone metastases in prostate cancer patients

Claire L. Ihle, Meredith D. Provera, Desiree M. Straign, E. Erin Smith, Susan M. Edgerton, Adrie Van Bokhoven, M. Scott Lucia & Philip Owens
Journal for ImmunoTherapy of Cancer 2019, 7:293 (8 November 2019)
Short Report


Primary prostate tumors are considered immunologically “cold” with low immune cell infiltration and minimal neoantigen expression, yet the immune environment within metastases has been less well-characterized, including any potential differences between the two primary types of secondary lesions: blastic and lytic. Claire Ihle and colleagues analyzed decalcified formalin-fixed and paraffin-embedded patient specimens from bone that contained metastatic prostate cancer with either lytic or blastic features using immunohistochemistry, the NanoString platform for gene expression analysis and the emerging Digital Spatial Profiling technology for molecular characterization of both tumor and stroma regions in the lesions. Both lytic and blastic lesions displayed evidence of sporadic infiltrating T cell populations by IHC. Lytic samples were enriched for expression of genes associated with the PI3K-AKT pathway, whereas blastic lesions displayed enrichment for expression of JAK-STAT signaling. Blastic-type samples showed increased expression of checkpoint inhibitor targets compared to lytic lesions, including PD-L1, PD-1, VISTA, OX40L and IDO-1. The study offers rationale for analyzing biopsies of secondary lesions to help identify optimal immunotherapeutic treatments for metastatic prostate cancer.

Immunostimulatory RNA leads to functional reprogramming of myeloid-derived suppressor cells in pancreatic cancer

Philipp Metzger, Sabrina V. Kirchleitner, Michael Kluge, Lars M. Koenig, Christine Hörth, Carlotta A. Rambuscheck, Daniel Böhmer, Julia Ahlfeld, Sebastian Kobold, Caroline C. Friedel, Stefan Endres, Max Schnurr & Peter Duewell
Journal for ImmunoTherapy of Cancer 2019, 7:288 (6 November 2019)


No immunotherapy-based approaches have been approved for the treatment of pancreatic ductal adenocarcinoma (PDAC), which is the second most common cause of cancer fatality among western nations. The use of Rig-I-like helicase (RLH) ligands to convert tumor microenvironments into immunologically “hot” sites has entered early clinical trials, and Philipp Metzger et al. provide mechanistic evidence that RLH ligands contribute to tumor control by T cells through reprogramming of myeloid-derived suppressor cells (MDSCs). Here they demonstrate in mouse models that the PDAC tumor microenvironment is characterized by low T cell infiltration and large populations of both monocytic and polymorphonuclear myeloid-derived suppressor cells ((M)-MDSC and (PMN)-MDSC), and that those suppressor cells profoundly suppress T cell activation (measured by interferon gamma production) in vitro. Treatment with the RLH ligand poly(I:C)c partially rescued the MDSC-mediated T cell suppression and shifted gene expression profiles toward a neutrophil-associated gene signature for PMN-MDSC and an M1-like signature M-MDSC. Type I interferon signaling was necessary for tumor control and MDSC reprogramming after poly(I:C)c treatment. The results offer rationale for the use of RLH-ligands in combination with other immunotherapy strategies such as checkpoint inhibitors or CAR T cells.

Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples

Eleanor M. Scott, Egon J. Jacobus, Brian Lyons, Sally Frost, Joshua D. Freedman, Arthur Dyer, Hena Khalique, William K. Taverner, Alison Carr, Brian R. Champion, Kerry D. Fisher, Len W. Seymour & Margaret R. Duffy
Journal for ImmunoTherapy of Cancer 2019, 7:320 (21 November 2019)


Selective depletion of M2-like tumor-associated macrophages (TAMs) within the tumor microenvironment could eliminate a key obstacle to the success of immunotherapy by eliminating stromal cells that promote disease progression through a tissue-remodeling and immunosuppressive phenotype, while sparing the M1-like TAMS that contribute to direct cancer cell killing in addition to T helper 1 immune responses. Eleanor Scott and colleagues have developed novel bivalent and trivalent antibodies recognizing CD3-epsilon and either CD206 or folate receptor beta (FR-beta) to redirect endogenous T cell toxicity specifically toward M2-like TAMs. In whole malignant ascites from cancer patients, the multi-specific antibodies triggered interferon gamma production and depletion of CD11b+ CD64+ (M2-like) macrophages. To alleviate potential on-target/off tumor effects if the agents were administered systemically, Scott et al. inserted the T cell engagers into the genome of EnAd, an oncolytic adenovirus currently being tested in phase 1/2 clinical trials. The engineered viruses retained oncolytic activity, while also causing a robust decline in CD11b+ CD64+ macrophages in malignant ascites from 5 cancer patients. Intriguingly, the remaining macrophages in the ascites displayed a general increase in M1-like marker expression. The study is the first to achieve selective depletion of M2-like TAM subsets, and describes an innovative two-in-one approach combining tumor microenvironment modification with oncolytic virotherapy.

Secondary resistance to immunotherapy associated with beta-catenin pathway activation or PTEN loss in metastatic melanoma

Jonathan A. Trujillo, Jason J. Luke, Yuanyuan Zha, Jeremy P. Segal, Lauren L. Ritterhouse, Stefani Spranger, Karen Matijevich & Thomas F. Gajewski
Journal for ImmunoTherapy of Cancer 2019, 7:295 (8 November 2019)


As many as 60% of melanoma patients who initially display objective responses to immunotherapy will subsequently relapse. Through molecular analyses of tumor biopsies, Jonathan Trujillo and colleagues describe two novel mechanisms of immunotherapy resistance in two patients, one of whom had been treated with a melanoma-peptide IL-12 vaccine and the other who received combination anti-CTLA-4/anti-PD-1 checkpoint blockade. Distinct from previously described mechanisms of immunotherapy resistance, antigen loss was not seen in either of the recurrent tumors after treatment. In both cases, initial treatment and partial responses were associated with CD8+ T cell infiltration into the tumor microenvironment, which was lost in secondary lesions—even though circulating tumor-specific memory T cells were still detected. T cell exclusion in the patient who was treated with the melanoma-peptide/IL-12 vaccine was associated with strong upregulation and nuclear localization of beta-catenin with an associated increase in beta-catenin regulated transcripts in relapsed tumor samples. Relapse after dual checkpoint blockade therapy was associated with bi-allelic loss of the tumor-suppressor gene PTEN in a new metastatic lesion. The study reveals new mechanisms of tumor outgrowth after immunotherapy, adding alterations in oncogenic signaling to the growing list of immunotherapy resistance pathways.

Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer

Harm Westdorp, Jeroen H. A. Creemers, Inge M. van Oort, Gerty Schreibelt, Mark A. J. Gorris, Niven Mehra, Michiel Simons, Anna L. de Goede, Michelle M. van Rossum, Alexandra J. Croockewit, Carl G. Figdor, J. Alfred Witjes, Erik H. J. G. Aarntzen, Roel D. M. Mus, Mareke Brüning, Katja Petry, Martin Gotthardt, Jelle O. Barentsz, I. Jolanda M. de Vries & Winald R. Gerritsen
Journal for ImmunoTherapy of Cancer 2019, 7:302 (14 November 2019)


The only U.S. FDA-approved cancer immunotherapy for castration-resistant prostate cancer (CRPC) is sipuleucel-T, an autologous antigen-presenting cell vaccine. The mechanism of action of sipuleucel-T remains ill-defined as the product contains roughly 60% CD3+ T cells and less than 20% CD54+ putative dendritic cells. In a randomized phase 2a trial encompassing 21 chemotherapy-naïve CRPC patients, Harm Westdorp and colleagues evaluated immunological responses as well as safety, feasibility, radiological progression-free survival (rPFS) and overall survival after intranodal vaccination with blood-derived CD1c+ myeloid dendritic cells (mDCs), plasmacytoid dendritic cells (pDCs) or a combination of the two. The dendritic cell vaccine products were loaded with NY-ESO-1, MAGE-C2 and MUC-1 peptides, and after vaccination, CD8+ T cells specific for each antigen were detected in the skin of 15 (71%), 12 (57%) and 5 (24%) patients, respectively. The median rPFS across all treatment arms was 9.5 months, and there was no significant difference between the mDC, pDC and combination groups. Interferon gamma producing tumor-antigen specific T cells were detected in skin-infiltrating lymphocytes from 5 of 13 patients with rPFS. In those 5 patients, rPFS was 18.8 months compared to 5.1 months for patients without interferon gamma producing antigen-specific T cells. No toxicities above grade 2 were reported. The trial reveals a new immune correlate that might be indicative of a beneficial response to DC vaccination. 

Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes

Minh Ngoc Duong, Efe Erdes, Michael Hebeisen & Nathalie Rufer
Journal for ImmunoTherapy of Cancer 2019, 7:284 (5 November 2019)

34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1

Journal for ImmunoTherapy of Cancer 2019, 7:282 (6 November 2019)
Meeting Abstracts

34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 2

Journal for ImmunoTherapy of Cancer 2019, 7:283 (5 November 2019)
Meeting Abstracts

Correction to: Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution

Vaia Florou, Andrew E. Rosenberg, Eric Wieder, Krishna V. Komanduri, Despina Kolonias, Mohamed Uduman, John C. Castle, Jennifer S. Buell, Jonathan C. Trent & Breelyn A. Wilky
Journal for ImmunoTherapy of Cancer 2019, 7:285 (6 November 2019)

Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system

Yinghong Zhai, Xiaofei Ye, Fangyuan Hu, Jinfang Xu, Xiaojing Guo, Yonglong Zhuang & Jia He
Journal for ImmunoTherapy of Cancer 2019, 7:286 (6 November 2019)

Antibiotic therapy and outcome from immune-checkpoint inhibitors

David J. Pinato, Daria Gramenitskaya, Daniel M. Altmann, Rosemary J. Boyton, Benjamin H. Mullish, Julian R. Marchesi & Mark Bower
Journal for ImmunoTherapy of Cancer 2019, 7:287 (6 November 2019)

Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma

Marieke J. Krimphove, Karl H. Tully, David F. Friedlander, Maya Marchese, Praful Ravi, Stuart R. Lipsitz, Kerry L. Kilbridge, Adam S. Kibel, Luis A. Kluth, Patrick A. Ott, Toni K. Choueiri & Quoc-Dien Trinh
Journal for ImmunoTherapy of Cancer 2019, 7:289 (7 November 2019)

Targeting of CXCR3 improves anti-myeloma efficacy of adoptively transferred activated natural killer cells

Valentina Bonanni, Fabrizio Antonangeli, Angela Santoni & Giovanni Bernardini
Journal for ImmunoTherapy of Cancer 2019, 7:290 (7 November 2019)

Moving forward to address key unanswered questions on targeting PD-1/PD-L1 in cancer: limitations in preclinical models and the need to incorporate human modifying factors

Catherine T. Le & William J. Murphy
Journal for ImmunoTherapy of Cancer 2019, 7:291 (7 November 2019)

Budesonide treatment for microscopic colitis from immune checkpoint inhibitors

Michael S. Hughes, Gabriel E. Molina, Steven T. Chen, Hui Zheng, Vikram Deshpande, Riley Fadden, Ryan J. Sullivan & Michael Dougan
Journal for ImmunoTherapy of Cancer 2019, 7:292 (7 November 2019)

Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME)

Anne Catherine Bretz, Ulrike Parnitzke, Kerstin Kronthaler, Tobias Dreker, René Bartz, Frank Hermann, Astrid Ammendola, Tanja Wulff & Svetlana Hamm
Journal for ImmunoTherapy of Cancer 2019, 7:294 (8 November 2019)

Guillain-Barre syndrome observed with adoptive transfer of lymphocytes genetically engineered with an NY-ESO-1 reactive T-cell receptor

Jocelyn Joseph, Michael J. Nathenson, Van Anh Trinh, Karan Malik, Erica Nowell, Kristen Carter, Shiao-Pei Weathers, George D. Demetri, Dejka Araujo & Anthony P. Conley
Journal for ImmunoTherapy of Cancer 2019, 7:296 (8 November 2019)
Case Report

Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status

Fotios Loupakis, Giulia Maddalena, Ilaria Depetris, Sabina Murgioni, Francesca Bergamo, Angelo Paolo Dei Tos, Massimo Rugge, Giada Munari, Andrew Nguyen, Christopher Szeto, Vittorina Zagonel, Sara Lonardi & Matteo Fassan
Journal for ImmunoTherapy of Cancer 2019, 7:297 (8 November 2019)
Case Report

Development and validation of an immune checkpoint-based signature to predict prognosis in nasopharyngeal carcinoma using computational pathology analysis

Ya-Qin Wang, Yu Zhang, Wei Jiang, Yu-Pei Chen, Shuo-Yu Xu, Na Liu, Yin Zhao, Li Li, Yuan Lei, Xiao-Hong Hong, Ye-Lin Liang, Jun-Yan Li, Lu-Lu Zhang, Jing-Ping Yun, Ying Sun, Ying-Qin Li & Jun Ma
Journal for ImmunoTherapy of Cancer 2019, 7:298 (13 November 2019)

Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study

Markus V. Heppt, Teresa Amaral, Katharina C. Kähler, Lucie Heinzerling, Jessica C. Hassel, Markus Meissner, Nicole Kreuzberg, Carmen Loquai, Lydia Reinhardt, Jochen Utikal, Evelyn Dabrowski, Anja Gesierich, Claudia Pföhler, Patrick Terheyden, Kai-Martin Thoms, Lisa Zimmer, Thomas K. Eigentler, Michael C. Kirchberger, Henner M. Stege, Friedegund Meier, Max Schlaak & Carola Berking
Journal for ImmunoTherapy of Cancer 2019, 7:299 (13 November 2019)

EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma

Gang Xiao, Li-Lian Jin, Chao-Qun Liu, Yong-Chun Wang, Ya-Ming Meng, Zhong-Guo Zhou, Jing Chen, Xing-Juan Yu, Yao-Jun Zhang, Jing Xu & Limin Zheng
Journal for ImmunoTherapy of Cancer 2019, 7:300 (14 November 2019)

Long-term survival without graft-versus-host-disease following infusion of allogeneic myeloma-specific V-beta T cell families

S. Yado, G. Luboshits, O. Hazan, R. Or & M. A. Firer
Journal for ImmunoTherapy of Cancer 2019, 7:301 (14 November 2019)

Anti-TNF, a magic bullet in cancer immunotherapy?

Anne Montfort, Carine Dufau, Céline Colacios, Nathalie Andrieu-Abadie, Thierry Levade, Thomas Filleron, Jean-Pierre Delord, Maha Ayyoub, Nicolas Meyer & Bruno Ségui
Journal for ImmunoTherapy of Cancer 2019, 7:303 (14 November 2019)

Mechanisms regulating PD-L1 expression on tumor and immune cells

Shuming Chen, George A. Crabill, Theresa S. Pritchard, Tracee L. McMiller, Ping Wei, Drew M. Pardoll, Fan Pan & Suzanne L. Topalian
Journal for ImmunoTherapy of Cancer 2019, 7:305 (15 November 2019)

Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors

Satya Das & Douglas B. Johnson
Journal for ImmunoTherapy of Cancer 2019, 7:306 (15 November 2019)

A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer

Hans-Georg Rammensee, Karl-Heinz Wiesmüller, P. Anoop Chandran, Henning Zelba, Elisa Rusch, Cécile Gouttefangeas, Daniel J. Kowalewski, Moreno Di Marco, Sebastian P. Haen, Juliane S. Walz, Yamel Cardona Gloria, Johanna Bödder, Jill-Marie Schertel, Antje Tunger, Luise Müller, Maximilian Kießler, Rebekka Wehner, Marc Schmitz, Meike Jakobi, Nicole Schneiderhan-Marra, Reinhild Klein, Karoline Laske, Kerstin Artzner, Linus Backert, Heiko Schuster, Johannes Schwenck, Alexander N. R. Weber, Bernd J. Pichler, Manfred Kneilling, Christian la Fougère, Stephan Forchhammer, Gisela Metzler, Jürgen Bauer, Benjamin Weide, Wilfried Schippert, Stefan Stevanović & Markus W. Löffler
Journal for ImmunoTherapy of Cancer 2019, 7:307 (15 November 2019)

The density and spatial tissue distribution of CD8+ and CD163+ immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors

Daniela Massi, Eliana Rulli, Mara Cossa, Barbara Valeri, Monica Rodolfo, Barbara Merelli, Francesco De Logu, Romina Nassini, Michele Del Vecchio, Lorenza Di Guardo, Roberta De Penni, Michele Guida, Vanna Chiarion Sileni, Anna Maria Di Giacomo, Marco Tucci, Marcella Occelli, Francesca Portelli, Viviana Vallacchi, Francesca Consoli, Pietro Quaglino, Paola Queirolo, Gianna Baroni, Fabrizio Carnevale-Schianca, Laura Cattaneo, Alessandro Minisini, Giuseppe Palmieri, Licia Rivoltini, Mario Mandalà & on behalf of the Italian Melanoma Intergroup
Journal for ImmunoTherapy of Cancer 2019, 7:308 (15 November 2019)

Dual checkpoint inhibitor-associated eosinophilic enteritis

J. Yang, S. M. Lagana, Y. M. Saenger & R. D. Carvajal
Journal for ImmunoTherapy of Cancer 2019, 7:310 (15 November 2019)
Case Report

Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment

Alice Newey, Beatrice Griffiths, Justine Michaux, Hui Song Pak, Brian J. Stevenson, Andrew Woolston, Maria Semiannikova, Georgia Spain, Louise J. Barber, Nik Matthews, Sheela Rao, David Watkins, Ian Chau, George Coukos, Julien Racle, David Gfeller, Naureen Starling, David Cunningham, Michal Bassani-Sternberg & Marco Gerlinger
Journal for ImmunoTherapy of Cancer 2019, 7:309 (18 November 2019)

Peritumoral administration of DRibbles-pulsed antigen-presenting cells enhances the antitumor efficacy of anti-GITR and anti-PD-1 antibodies via an antigen presenting independent mechanism

Jaina M. Patel, Zhihua Cui, Zhi-Fa Wen, Catherine T. Dinh & Hong-Ming Hu
Journal for ImmunoTherapy of Cancer 2019, 7:311 (20 November 2019)

Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients

Lenka Kasikova, Michal Hensler, Iva Truxova, Petr Skapa, Jan Laco, Lucie Belicova, Ivan Praznovec, Sarka Vosahlikova, Michael J. Halaska, Tomas Brtnicky, Lukas Rob, Jiri Presl, Jan Kostun, Isabelle Cremer, Ales Ryska, Guido Kroemer, Lorenzo Galluzzi, Radek Spisek & Jitka Fucikova
Journal for ImmunoTherapy of Cancer 2019, 7:312 (20 November 2019)

Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer

Colby S. Shemesh, Pascal Chanu, Kris Jamsen, Russ Wada, Gianluca Rossato, Francis Donaldson, Amit Garg, Helen Winter, Jane Ruppel, Xin Wang, Rene Bruno, Jin Jin & Sandhya Girish
Journal for ImmunoTherapy of Cancer 2019, 7:314 (21 November 2019)

Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma

Jia Wei, Xiaojian Zhu, Xia Mao, Liang Huang, Fankai Meng & Jianfeng Zhou
Journal for ImmunoTherapy of Cancer 2019, 7:315 (21 November 2019)
Case Report

Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer

Lorenza Landi, Federica D’Incà, Alain Gelibter, Rita Chiari, Francesco Grossi, Angelo Delmonte, Antonio Passaro, Diego Signorelli, Francesco Gelsomino, Domenico Galetta, Diana Giannarelli, Hector Soto Parra, Gabriele Minuti, Marcello Tiseo, Maria Rita Migliorino, Francesco Cognetti, Luca Toschi, Paolo Bidoli, Francovito Piantedosi, Luana Calabro’ & Federico Cappuzzo
Journal for ImmunoTherapy of Cancer 2019, 7:316 (21 November 2019)

Radiation myelitis after pembrolizumab administration, with favorable clinical evolution and safe rechallenge: a case report and review of the literature

Marcela Carausu, Arnaud Beddok, Adriana Langer, Nicolas Girard, François-Clément Bidard, Marie-Ange Massiani, Damien Ricard & Luc Cabel
Journal for ImmunoTherapy of Cancer 2019, 7:317 (21 November 2019)
Case Report

Immune induction strategies to enhance responses to PD-1 blockade: lessons from the TONIC trial

Sandra Demaria, Emanuela Romano, Muriel Brackstone & Silvia C. Formenti
Journal for ImmunoTherapy of Cancer 2019, 7:318 (21 November 2019)

Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature

Houssein Safa, Daniel H Johnson, Van Anh Trinh, Theresa E Rodgers, Heather Lin, Maria E Suarez-Almazor, Faisal Fa’ak, Chantal Saberian, Cassian Yee, Michael A Davies, Sudhakar Tummala, Karin Woodman, Noha Abdel-Wahab & Adi Diab
Journal for ImmunoTherapy of Cancer 2019, 7:319 (21 November 2019)

Sarcosine promotes trafficking of dendritic cells and improves efficacy of anti-tumor dendritic cell vaccines via CXC chemokine family signaling

Farhad Dastmalchi, Aida Karachi, Changlin Yang, Hassan Azari, Elias Joseph Sayour, Anjelika Dechkovskaia, Alexander Loren Vlasak, Megan Ellen Saia, Rolando Eladio Lovaton, Duane Anthony Mitchell & Maryam Rahman
Journal for ImmunoTherapy of Cancer 2019, 7:321 (21 November 2019)

Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition

Xuanye Zhang, Yixin Zhou, Chen Chen, Wenfeng Fang, Xiuyu Cai, Xiaoshi Zhang, Ming Zhao, Bei Zhang, Wenqi Jiang, Zuan Lin, Yuxiang Ma, Yunpeng Yang, Yan Huang, Hongyun Zhao, Ruihua Xu, Shaodong Hong & Li Zhang
Journal for ImmunoTherapy of Cancer 2019, 7:322 (21 November 2019)

TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma

Matthew J. Reilley, Brittany Morrow, Casey R. Ager, Arthur Liu, David S. Hong & Michael A. Curran
Journal for ImmunoTherapy of Cancer 2019, 7:323 (26 November 2019)
Short Report

IL-17 inhibits CXCL9/10-mediated recruitment of CD8+ cytotoxic T cells and regulatory T cells to colorectal tumors

Ju Chen, Xiaoyang Ye, Elise Pitmon, Mengqian Lu, Jun Wan, Evan R. Jellison, Adam J. Adler, Anthony T. Vella & Kepeng Wang
Journal for ImmunoTherapy of Cancer 2019, 7:324 (27 November 2019)

Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?

Andrew B. Nixon, Kurt A. Schalper, Ira Jacobs, Shobha Potluri, I-Ming Wang & Catherine Fleener
Journal for ImmunoTherapy of Cancer 2019, 7:325 (27 November 2019)

Ginseng-derived nanoparticles alter macrophage polarization to inhibit melanoma growth

Meng Cao, Huaijiang Yan, Xuan Han, Ling Weng, Qin Wei, Xiaoyan Sun, Wuguang Lu, Qingyun Wei, Juan Ye, Xueting Cai, Chunping Hu, Xiaoyang Yin & Peng Cao
Journal for ImmunoTherapy of Cancer 2019, 7:326 (27 November 2019)

MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment

Douglas D. Fang, Qiuqiong Tang, Yanhui Kong, Qixin Wang, Jiaxing Gu, Xu Fang, Peng Zou, Tao Rong, Jingwen Wang, Dajun Yang & Yifan Zhai
Journal for ImmunoTherapy of Cancer 2019, 7:327 (28 November 2019)

Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery

Molly A. Taylor, Adina M. Hughes, Josephine Walton, Anna M. L. Coenen-Stass, Lukasz Magiera, Lorraine Mooney, Sigourney Bell, Anna D. Staniszewska, Linda C. Sandin, Simon T. Barry, Amanda Watkins, Larissa S. Carnevalli & Elizabeth L. Hardaker
Journal for ImmunoTherapy of Cancer 2019, 7:328 (28 November 2019)

Immunotherapy response evaluation with magnetic resonance elastography (MRE) in advanced HCC

Aliya Qayyum, Ken-Pin Hwang, Jason Stafford, Anuj Verma, Dipen M. Maru, Subramanya Sandesh, Jia Sun, Roberto Carmagnani Pestana, Rony Avritscher, Manal M. Hassan, Hesham Amin, Asif Rashid, Ignacio I. Wistuba, Richard L. Ehman, Jingfei Ma & Ahmed O. Kaseb
Journal for ImmunoTherapy of Cancer 2019, 7:329 (28 November 2019)
Short Report

Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity

Alejandro Torres Chavez, Mary Kathryn McKenna, Emanuele Canestrari, Christina T. Dann, Carlos A. Ramos, Premal Lulla, Ann M. Leen, Juan F. Vera & Norihiro Watanabe
Journal for ImmunoTherapy of Cancer 2019, 7:330 (28 November 2019)

PD1Hi CD8+ T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma

Jiaqiang Ma, Bohao Zheng, Shyamal Goswami, Lu Meng, Dandan Zhang, Chunmei Cao, Teng Li, Fangming Zhu, Lijie Ma, Zhao Zhang, Shuhao Zhang, Meng Duan, Qin Chen, Qiang Gao & Xiaoming Zhang
Journal for ImmunoTherapy of Cancer 2019, 7:331 (29 November 2019)

Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge 2018” (28–29 November, 2018, Naples, Italy)

Paolo A. Ascierto, Carlo Bifulco, Luigi Buonaguro, Leisha A. Emens, Robert L. Ferris, Bernard A. Fox, Greg M. Delgoffe, Jérôme Galon, Cesare Gridelli, Marco Merlano, Paul Nathan, Kunle Odunsi, Hideho Okada, Chrystal M. Paulos, Sandro Pignata, Kurt A. Schalper, Stefani Spranger, Giampaolo Tortora, Hassane Zarour, Lisa H. Butterfield & Igor Puzanov
Journal for ImmunoTherapy of Cancer 2019, 7:332 (29 November 2019)

Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions

Marc Hilmi, Cindy Neuzillet, Julien Calderaro, Fouad Lafdil, Jean-Michel Pawlotsky & Benoit Rousseau
Journal for ImmunoTherapy of Cancer 2019, 7:333 (29 November 2019)

Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patients

Qinchuan Wang, Jinhua Zhang, Huakang Tu, Dong Liang, David. W. Chang, Yuanqing Ye & Xifeng Wu
Journal for ImmunoTherapy of Cancer 2019, 7:334 (29 November 2019)

SITC Members Receive 60 Percent Submission Discount in 2019

*As a way to thank the SITC members who work tirelessly to advance the science and improve the lives of cancer patients, SITC will provide SITC members with a 60 percent discount on processing fees for all JITC articles accepted in 2019. Membership verification will be required upon post-review acceptance.